Hormone Replacement Therapy with Estradiol

Introduction to HRT Regimens

The American College of Obstetricians and Gynecologists recommends starting postmenopausal women on transdermal patches releasing 50 μg of 17β-estradiol daily, applied twice weekly, with mandatory addition of progestin for women with an intact uterus to prevent endometrial cancer 1, 2

The standard starting dose for HRT is 50 μg daily, which should be maintained as the lowest effective dose, according to the North American Menopause Society 1
Transdermal 17β-estradiol is strongly preferred as first-line therapy over oral formulations, particularly in cancer survivors and women at increased cardiovascular risk, due to its superior cardiovascular and thrombotic risk profile, as recommended by the American Heart Association 3, 1

Women with an intact uterus must receive progestin supplementation to reduce endometrial cancer risk, with micronized progesterone 200 mg daily for 12-14 days every 28 days being the first choice, due to its superior cardiovascular and thrombotic risk profile, as recommended by the American College of Obstetricians and Gynecologists 3, 1, 4
Alternative sequential options include medroxyprogesterone acetate (MPA) 10 mg daily for 12-14 days per month and dydrogesterone 10 mg daily for 12-14 days per month, as suggested by the Endocrine Society 3, 1, 4

Young women with premature ovarian insufficiency require the same 50 μg/24-hour patches changed twice weekly, with transdermal 17β-estradiol strongly recommended as first-line therapy due to higher cardiovascular risk in cancer survivors and superior bone mass accrual, as recommended by the American Society for Reproductive Medicine 3, 2
Treatment should continue until the average age of natural menopause (45-55 years), according to the North American Menopause Society 4

Never prescribe estrogen alone to women with an intact uterus, as this dramatically increases endometrial cancer risk, as warned by the American College of Obstetricians and Gynecologists 1
Do not start with doses higher than 50 μg daily, as this increases harm without additional benefit, as recommended by the Endocrine Society 1